International Clinical Trial: A Phase II Study of Cetuximab in TERT Promoter Mutant Oral Cavity Cancer After Failure of Platinum-Based Chemotherapy and/or Immune Checkpoint Inhibitors

Geneva, March 20 -- International Clinical Trials Registry received information related to the study (KCT0011650) titled 'A Phase II Study of Cetuximab in TERT Promoter Mutant Oral Cavity Cancer After Failure of Platinum-Based Chemotherapy and/or Immune Checkpoint Inhibitors' on Feb. 25.

Study Type: Interventional Study

Study Design: Primary Purpose : Treatment, Intervention Model : Single Group, Blinding/Masking : Open, Allocation : Not Applicable

Primary Sponsor: Seoul National University Hospital

Condition:

Neoplasms

Intervention: Drug : Cetuximab (, Erbitux Injection) : Every 2weeks 500mg/m² ? Cetuximab 00 mg/m² dosing (IV) every 2 weeks (±2 days): at D1 and D15 in each 28 day cycle Administration in IV (1 cycl...